KRAS and neoplasm: However, the effect of using antiangiogenic drugs beyond progression regarding OS was weaker in the subgroup of women (n = 1,047) with a HR of 0.81 (95%-CI, 0.70–0.94) and not statistically significant for patients bearing a tumor with KRAS mutation (n = 1,260) with a HR of 0.89 (95%-CI, 0.78–1.02).